From Market Places to Problem Places: Report of the Quebec Seeks Solutions Conference -- A New Method for Open Innovation

News - More than 170 persons joined as active problem solvers in a packed room in the Quebec convention center on Dec 14. The idea of the event was simple: Turn a science conference upside down.

Smart 21 Community 2011: Quebec City’s genius is finally recognized!

News - On October 22, Quebec City gained another international distinction when it was named one of the Top 21 most intelligent communities (Smart 21 Community 2011) by the Intelligent Community Forum (ICF), a New York-based independent think tank dedicated to developing the digital economy. The announcement was made by Louis Zacharilla, one of the ICF’s founders, at a ceremony in Suwon, South Korea.

Desjardins Group, Canada's leading cooperative financial group, named Bank of the Year 2010 - Canada by The Banker

News - Within days of its 110th anniversary, Desjardins Group, Canada’s leading cooperative financial group, has been named Bank of the Year 2010 - Canada by the prestigious British magazine, The Banker, published by The Financial Times. This is the first time in Desjardins' history that it has participated in this competition and it’s the first time that a Canadian cooperative financial institution has won.

The Three Laws of Export Success

News - An article by Perry B. Newman, President of Atlantica Group LLC published on November 18, 2010 in Corp! Magazine

Why Québec City is a Rising Star

News - Blog by John Parisella: National unemployment rates often overshadow the work of some communities in transforming their economic profiles. Cities like Raleigh NC have transformed their economy and others like Des Moines IA have significantly lowered their unemployment rates. Another below the radar screen example is Québec City, Canada.

Up to $330M CAD international partnership between Bayer Healthcare Pharmaceuticals and Endoceutics Inc.

News - Bayer HealthCare Pharmaceuticals (Bayer) and EndoCeutics Inc., Québec, are proud to announce the signing of an exclusive international collaborative agreement for Phase III development and marketing of Dehydroepiandrosterone (DHEA), a new treatment for vaginal atrophy and female sexual dysfunction. Bayer’s partnership with EndoCeutics Inc. may mean up to approximately $330 million dollars CAD in milestones and research costs. To this amount will be added royalties based upon the sales of the compound by Bayer. This agreement includes financing for clinical trials in Canada and the United States and will be paid to EndoCeutics Inc.


Subscribe to our newsletter for interesting news and information.

Print this page